We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
+$145M
Cap. Flow %
8.42%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.15%
2 Healthcare 18.37%
3 Financials 0.23%
4 Technology 0.2%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
301
CALL
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-2,584
Closed -$1.14M
CYH icon
302
Community Health Systems
CYH
$419M
– –
-31,122
Closed -$359K
CYH icon
303
PUT
Community Health Systems
CYH
$419M
– –
-413
Closed -$477K
DXCM icon
304
CALL
DexCom
DXCM
$32.6B
– –
-3,224
Closed -$7.07M
ELDN icon
305
Eledon Pharmaceuticals
ELDN
$220M
– –
-1,985
Closed -$492K
EVOK
306
DELISTED
Evoke Pharma
EVOK
– –
-443
Closed -$144K
EXAS
307
PUT
DELISTED
Exact Sciences
EXAS
– –
-1,153
Closed -$2.14M
KYNB
308
Kyntra Bio
KYNB
$31.5M
– –
-2,907
Closed -$1.45M
GALT icon
309
Galectin Therapeutics
GALT
$376M
– –
-87,999
Closed -$78.2K
GILD icon
310
PUT
Gilead Sciences
GILD
$181B
– –
-771
Closed -$6.1M
HUM icon
311
PUT
Humana
HUM
$47.6B
– –
-700
Closed -$12.4M
INCY icon
312
CALL
Incyte
INCY
$24.7B
– –
-36
Closed -$339K
LRMR icon
313
CALL
Larimar Therapeutics
LRMR
$406M
– –
-179
Closed -$15K
MNKD icon
314
MannKind Corp
MNKD
$1.14B
– –
-357,074
Closed -$1.03M
NSPR icon
315
InspireMD
NSPR
$36.1M
– –
-1
Closed -$54K
NTRA icon
316
CALL
Natera
NTRA
$50.6B
– –
-145
Closed -$161K
NUWE icon
317
Nuwellis
NUWE
$2.68M
– –
0
– -$518K
NVAX icon
318
PUT
Novavax
NVAX
$1.52B
– –
-42
Closed -$176K
NVO
319
PUT
Novo Nordisk
NVO
$188B
– –
-1,718
Closed -$3.57M
OCUL icon
320
Ocular Therapeutix
OCUL
$2.24B
– –
-38,100
Closed -$262K
OEF icon
321
CALL
iShares S&P 100 ETF
OEF
$20.1B
– –
-5,441
Closed -$67.6M
QRHC icon
322
Quest Resource Holding
QRHC
$28.9M
– –
-138,980
Closed -$281K
RGLS
323
CALL
DELISTED
Regulus Therapeutics
RGLS
– –
-92
Closed -$3.63M
RIGL icon
324
CALL
Rigel Pharmaceuticals
RIGL
$829M
– –
-32
Closed -$116K
SPY icon
325
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$799B
– –
-10,000
Closed -$216M
11 12
13
14 15

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management deployed $145M of net new capital in Q4 2016, opening 67 new positions and adding to 88 existing holdings. Its largest new stake was Eli Lilly: 213,113 shares worth $15.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, down from 90% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Regenxbio, an estimated $4.1M trimmed.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.